CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma Feb 01, 2024 8:30am EST Press Release
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO Jan 29, 2024 8:30am EST Press Release
CytoDyn Announces Company Updates and Investment Community Update Webcast Jul 11, 2023 4:05pm EDT Press Release